Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol

Human Reproduction

Volumn 22, Issue 7, 2007, Pages 1912-1918

  Aronsson, Annette ^a   Fiala, C ^a,b   Stephansson, O ^a   Granath, F ^a   Watzer, B ^c   Schweer, H ^c   Gemzell Danielsson, K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Gynmed Clinic   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Induced abortion; Misoprostol; Pharmacokinetics; Slow release

Indexed keywords

ANALGESIC AGENT; IBUPROFEN; MISOPROSTOL; PARACETAMOL;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; INDUCED ABORTION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SLOW DRUG RELEASE; TABLET; TANDEM MASS SPECTROMETRY; VOMITING;

EID: 34447311934     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem098     Document Type: Article

References (25)

1. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of Misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004;19:81-84.
2. Blanchard K, Clark S, Coyaji K et al. Misoprostol for wome's health: A review. Obstet Gynecol 2002;99:316-332.
3. Chen D, Tsay R-J, Lin H-I et al. Stabilization and sustained-release effect of misoprostol with metharylate copolymer. Int J Pharm 2000;203:141-148.
4. Cicinelli C, De Ziegler D, Bulletti C et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000b;95 403-406.
5. Cicinelli C, Schonauer LM, Galantino P et al. Mechanisms of uterine specifity of vaginal progesterone. Hum Reprod 2000a;15 159-165.
6. Csapo A. Progesterone block. Am J Anat 1956;98:273-291.
7. El-Refaey H, Rajasekar D, Abdalla M et al. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Eng J Med 1995;332:983-987.
8. Fiala C, Aronsson A, Granath F et al. Pharmacokinetics of a novel oral slow-release form of misoprostol. Hum Reprod 2005b;20 3414-3418.
9. Fiala C. Aronsson A, Stephansson O et al. Effects of slow release misoprostol on uterine contractility in early pregnancy. Hum Reprod 2005a;20:2648-2652.
10. Gemzell-Danielsson K, Marions L, Rodriguez. A et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynaecol 1999;93:275-280.
11. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001;344:38-47.
12. Hamoda H, Ashok PW, Flett GM et al. A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Am J Obstet Gynecol 2004;190:55-59.
13. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
14. Khan R, El-Refaey H, Sharma S et al. Oral, rectal and vaginal pharmacokinetics of misoprostol. Obstet Gynaecol 2004;103 866-870.
15. Mc Kinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993;8:1502-1505.
16. Meckstroth KR, Whitaker AK, Bertisch S et al. Misoprostol administered by epithelial routes. Obstet Gynaecol 2006;108 582-590.
17. Robert A, Nezamis JE, Phillips JP. Inhibition of gastric secretion by prostaglandins. Am J Dig Dis 1967;12:1073-1076.
18. SAS Institute Inc. SAS/STATTM Software: SAS Institute Inc., Cary, NC, 1997.
19. Scheepers HC, van Erp EJ, van den Bergh AS. Use of misoprostol in first and second trimester abortion: A review. Obstet Gynecol Surv 1999;54 592-600.
20. Tang OS, Lau WNT, Chan CCW et al. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004;111:1001-1005.
21. Tang OS, Schweer H, Seyberth HW et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002;17:332-336.
22. Watkinson G, Hopkins A, Akbar FA. The therapeutic efficacy of misoprostol in peptic ulcer disease. Postgrad Med J 1988;64 60-77.
23. Watzer B, Seyberth HW, Schweer H. Determination of misoprostol free acid in human breast milk and serum by gas chromotography/negative ion chemical ionization tandem mass spectrometry. J Mass Spectrom 2002;37:927-933.
24. World Health Organization. Medical methods for termination of pregnancy, WHO technical report series 871, 1997.
25. Zieman M, Fong SK, Benowitz NL et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997;90:88-92.